Table 3 Univariate and multivariate analyses of clinical pathological parameters in CRC patients
From: Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
Hazard ratio (95% CI) | p-Value | Hazard ratio (95% CI) | p-Value | ||
Age | 284 | ||||
≤ 60 | 102 | Reference | |||
> 60 | 182 | 1.058(0.838–1.799) | 0.291 | 1.420 (0.845–2.565) | 0.334 |
Gender | 284 | ||||
Female | 134 | Reference | |||
Male | 150 | 0.755 (0.458–1.334) | 0.218 | 0.8585(0.418–1.708) | 0.899 |
Histologic grade | 286 | ||||
G1 | 41 | Reference | |||
G2 | 68 | 1.224 (0.586–1.996) | 0.598 | 0.825 (0.437–1.822) | 0.508 |
G3-G4 | 187 | 1.222 (0.710–2.103) | 0.484 | 1.041 (0.685–1.996) | 0.994 |
T stage | 248 | ||||
T1 and T2 | 158 | Reference | |||
T3 and T4 | 90 | 2.052 (1.661–3.241) | 0.014 | 2.255 (1.041–4.014) | 0.011 |
M stage | 268 | ||||
M0 | 264 | Reference | |||
M1 | 4 | 1.589 (1.007–3.288) | 0.012 | 1.085 (0.865–2.583) | 0.331 |
N stage | 258 | ||||
N0 | 253 | Reference | |||
N1 | 3 | 1.156 (0.855–2.609) | 0.344 | 1.186 (0.685–2.968) | 0.481 |
CXCL5 | 336 | 1.058 (0.755–1.969) | 0.004 | 1.035 (0.758–1.958) | 0.028 |
Pathologic stage | 308 | ||||
Stage I | 148 | Reference | |||
Stage II- IV | 160 | 1.256 (1.008–2.668) | 0.002 | 1.355 (0.868–2.055) | 0.314 |